BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients

Completed

Conditions: Magnetic Resonance Imaging
Magnetic Resonance Angiography

Interventions: Drug: Gadobutrol (Gadovist, BAY86-4875)

First Posted Date: 2010-03-29

Last Posted Date: 2015-01-21

Lead Sponsor: Bayer

Target Recruit Count: 23775

Registration Number: NCT01095081

NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)

Phase 4

Terminated

Conditions: Hypogonadism

Interventions: Drug: Placebo
Drug: Testosterone Undeconate (Nebido, BAY86-5037)

First Posted Date: 2010-03-25

Last Posted Date: 2014-11-05

Lead Sponsor: Bayer

Target Recruit Count: 4

Registration Number: NCT01092858

MiCo - Mirena or Conventional Medical Treatment for Menorrhagia

Completed

Conditions: Idiopathic Menorrhagia

Interventions: Drug: Levonorgestrel (Mirena, BAY86-5028)
Drug: Hormonal treatment
Drug: Antifibrinolytic treatment

First Posted Date: 2010-03-12

Last Posted Date: 2012-04-10

Lead Sponsor: Bayer

Target Recruit Count: 1211

Registration Number: NCT01085487

Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites

Phase 1

Completed

Conditions: Contraception

Interventions: Drug: Gestodene/EE Patch (BAY86-5016)

First Posted Date: 2010-03-09

Last Posted Date: 2014-06-23

Lead Sponsor: Bayer

Target Recruit Count: 43

Registration Number: NCT01083264

Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Aspirin Aspro
Drug: Acetylsalicylic Acid (Aspirin BAY1019036)
Drug: Alka Seltzer Extra Strength
Drug: Aspirin Migraine

First Posted Date: 2010-03-05

Last Posted Date: 2014-06-26

Lead Sponsor: Bayer

Target Recruit Count: 26

Registration Number: NCT01081353

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2010-02-26

Last Posted Date: 2015-07-03

Lead Sponsor: Bayer

Target Recruit Count: 73

Registration Number: NCT01076595

Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)

Phase 3

Completed

Conditions: Intragastric Acidity

Interventions: Drug: Zegerid
Drug: Prilosec OTC™ Tablets
Other: Placebo

First Posted Date: 2010-02-26

Last Posted Date: 2015-03-11

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT01077076

Comparative Trial in Hormone Withdrawal Associated Symptoms

Phase 3

Completed

Conditions: Oral Contraceptive

Interventions: Drug: EE20/DRSP (YAZ, BAY86-5300)
Drug: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)

First Posted Date: 2010-02-26

Last Posted Date: 2014-10-28

Lead Sponsor: Bayer

Target Recruit Count: 592

Registration Number: NCT01076582

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039)
Drug: Moxifloxacin (BAY12-8039)

First Posted Date: 2010-02-23

Last Posted Date: 2015-07-01

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT01073891

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension

Phase 1

Completed

Conditions: Anti-Infective Agents

Interventions: Drug: Cephalexin suspension (Optocef, BAYO5448)
Drug: Cephalexin suspension (Keflex)

First Posted Date: 2010-02-23

Last Posted Date: 2014-04-03

Lead Sponsor: Bayer

Target Recruit Count: 26

Registration Number: NCT01073540

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy